CORT Biomarker Study


• Male or female, age 18 or older
• Signed the informed consent form
• Scleroderma as defined by the American College of Rheumatology or defined as healthy control (subject without a known autoimmune or inflammatory disease)
• Willing and able to participate for the 5 year duration of the study


• Clinically significant pulmonary, renal, cardiac, gastrointestinal or vascular disease which is not due to SSc. This would include secondary causes of pulmonary hypertension such as embolic disease or other organ involvement with apparent defined cause diagnosed before the initial study screening encounter
• Diagnosis of any malignancy within the previous 2 years, excluding adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ
• Presence of other co-morbid illnesses with an estimated median life expectancy <5 years